Intellia says FDA accepted BLA for lonvo-z
Intellia said the FDA accepted the BLA for lonvo-z, granted Priority Review and set a PDUFA action date of March 10, 2027.
Key Highlights:Original SEC Filing: Intellia Therapeutics, Inc. [ NTLA ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain inaccuracies.
Consider verifying import…